Superantigens are products of bacteria with dual affinity for HLA-DR and the variable region of the ft chain of the T cell receptor, leading to the stimulation of large numbers of T cells. Because there is evidence for the involvement of superantigens in various disease conditions in which intravenous IgG (IVIgG) is used as therapy, the purpose of the present study was to determine if IVIgG contains antibodies inhibitory to T cell stimulation by the superantigens. ELISA and Western assays revealed high concentrations of antibodies in the pooled IgG against eight different staphylococcal toxin (Staph-toxin) superantigens. The IVIgG inhibited in vitro stimulation of human peripheral blood T cells by the Staph-toxins, but did not inhibit responses elicited by phytohemagglutinin or anti-CD3. Inhibition was mediated by Staph-toxin-specific antibodies as shown by affinity adsorption depletion studies. The antibodies functioned by inhibiting the binding and/or presentation of Staphtoxins by DR' accessory cells. In conclusion, this report is the first to show that normal pooled IgG contains antibodies against a major group of the superantigens, the Staph-toxins, and that the antibodies can inhibit Staph-toxin-elicited T cell activation, suggesting a possible immunoregulatory role for the antibodies in vivo. (J. Clin. Invest. 1993. 91:602-607.)
Introduction
Superantigens are a class of bacterially derived substances which stimulate a large fraction of the T cell population without requiring previous sensitization (1) (2) (3) (4) (5) (6) (7) (8) . T cell stimulation is mediated by the dual affinity of superantigens for the class II major histocompatibility complex on accessory cells and for the relatively invariant sequence of the variable (V) fi region of the T cell receptor (TCR)' (1) (2) (3) (4) (5) (6) (7) (8) . Depending on the superanti- 1 . Abbreviations used in this paper: IVIgG, intravenous immunoglobulin G; SEB, staphylococcal enterotoxin B; SEE, staphylococcal enterotoxin E; Staph-toxins, staphylococcal toxins; TCR, T cell receptor; TSST-1, toxic shock syndrome toxin-1; V, variable. gen, T cells of different V # families are stimulated (2, 8) . The staphylococcal toxins (Staph-toxins) comprise a major group of superantigens which have been highly purified and well characterized in terms of their effects on T cells (3, 8) .
Superantigens may be involved in dysregulation of the immune system, contributing to a number ofdiverse diseases (9) (10) (11) (12) (13) (14) (15) . The Staph-toxins have major effects on the immune system in vivo, causing the initial activation oflarge numbers ofT cells, resulting in the expansion of various V fi T cell families, followed by their anergy and deletion ( 16, 17) . Superantigens have been implicated in the clonal expansion of T cells observed in toxic shock syndrome (11) , rheumatoid arthritis ( 12) , and Kawasaki disease ( 13) and in the deletion of T cells seen in human immunodeficiency virus (HIV) infection (14, 15) .
Because superantigens may be involved in diseases in which intravenous IgG (IVIgG) is used as therapy (18) (19) (20) (21) (22) , the present study was undertaken to determine whether or not IVIgG contained antibodies that inhibited T cell activation by the Staph-toxins. IVIgG is a pool of IgG derived from a large number of normal donors (> 6,000) (18) (19) (20) (21) (22) , which can supply protective antibodies against infectious agents in immunocompromised individuals. The role of pooled IgG in abrogating symptoms in autoimmune diseases is less well established ( 18) . The present study shows that pooled IgG contains high concentrations of Staph-toxin-specific antibodies which are highly inhibitory to the in vitro activation of T cells by the Staph-toxins.
Methods
Reagents and cell lines. Two pooled human IgG preparations were purchased for this study: pool 1, Venoglobulin I (Alpha Therapeutic Corp., Los Angeles, CA); and pool 2, Sandoglobulin (Sandoz Pharmaceutical Corp., East Hanover, NJ). Each preparation was from a different pool of at least 6,000 normal healthy adult donors within the United States. Pool 1 was used in all of the studies reported herein, except Table I in which both pools were used. Purified human monoclo-Measurement ofantibodies to the Staph-toxins. The enzyme-linked immunosorbent assay (ELISA) was performed as described by Walker et al. (23) . Assay wells were coated with 5 Ag/ml (0.5 ug per well) toxin. Pooled IgG preparations (adjusted to 10 mg/ml to approximate the normal serum IgG level) were diluted 1:1,000 or greater. Bound IgG was detected by addition ofan affinity-purified F(ab)2 preparation of rabbit anti-human IgG specific for Fc and conjugated with peroxidase (Rockland, Inc., Gilbertsville, PA). Each dilution of pooled IgG was assayed in duplicate on nonantigen-coated (background) and antigen-coated wells; background values, which averaged < 0.010OD, were subtracted from the antigen-coated well values. The concentration of antibody in each IgG preparation was defined as the reciprocal dilution of the sample giving an OD of 0.2 extrapolated from a standard curve. The relationship between absorbance and the dilution of IgG was linear on a log-log plot between an OD of0.05 and 1.50, with a similar slope of binding for each toxin (data not shown).
Western blot analysis. The various Staph-toxins (0.3 fg) were separated electrophoretically on polyacrylamide ( 12%) slab gels with SDS (Bio-Rad Laboratories, Richmond, CA). Pooled IgG was assayed at 20
,gg/ml. Bound IgG was detected with the same peroxidase-labeled IgG specific antiserum used in the ELISA. Affinity adsorption ofSEB specific antibodies. SEB (0.5 mg) was coupled to cyanogen bromide-activated Sepharose (24) . 10 mg of pooled IgG was adsorbed by mixing with the SEB-coupled Sepharose for 45 min at room temperature. The adsorbed IgG was removed by centrifugation, the adsorbent was washed six times, and the bound IgG was eluted with sodium thiocyanate (3 M with 0.015 M potassium phosphate buffer, pH 6.6). The eluate was subsequently dialyzed and assayed for IgG concentration and for specific antibodies by ELISA.
Lymphoid cell preparation and culture. Peripheral blood lymphocytes were prepared by centrifugation of heparinized blood from normal individuals on Ficoll-Paque (Pharmacia, Inc., Piscataway, NJ). Interleukin 2 (IL-2) assay. IL-2 was assayed on the IL-2-dependent murine CTLL cell line (25) binding was directed against the Staph-toxins. Fig. 1 shows that pooled IgG bound predominantly to proteins in the 20-30 kD range, the approximate molecular weights of the Staph-toxins (2, 26) . In the case of exfoliative toxin (Exfol), the IgG bound to additional proteins, but the majority of the binding was in the 29-kD area.
Specificity ofbinding. Experiments were performed to ensure that binding by the pooled IgG to the Staph-toxins was mediated by specific antibody. Table II shows that an F(ab)2 preparation of pooled IgG bound to the toxins as strongly as did whole IgG (Table I) Inhibition by specific antibodies. To determine whether or not inhibition of T cell proliferation was mediated by specific antibodies, we first examined whether inhibition was mediated by the Fab region of the pooled IgG. Fig. 3 (top panel) shows that the F(ab)2 preparation of pooled IgG inhibited T cell activation by SEB to a similar degree as whole pooled IgG, whereas the Fc fragment of pooled IgG was not inhibitory. Fig. 3 (bottom panel) also shows that the monoclonal IgG, which lacked antibodies to the Staph-toxins (Table II) , was not inhibitory to Staph-toxin-elicited proliferation, even at a relatively high concentration (1 mg/ml).
Inhibition by Staph-toxin-specific antibodies. Fig. 4 shows that pooled IgG depleted of SEB-specific antibodies lost most ofits ability to inhibit T cell activation by SEB, but retained the ability to inhibit the response to TSST-1. In contrast, antibodies eluted from the SEB adsorbent were strongly inhibitory to the SEB response, but not to the TSST-1 response. The eluted antibodies were inhibitory in nanogram concentrations, showing a significant increase in specific inhibitory activity. Thus, Staph-toxin specific antibodies appear to mediate the inhibition by pooled IgG.
Cell site of inhibition. Because proliferation is a relatively late event in T cell activation, the effect of pooled IgG on an earlier event, the production of IL-2, was examined. Table III shows that IL-2 production in response to SEB was inhibited by pooled IgG to the essentially same extent as proliferation. The inhibition ofIL-2 production suggested that antibodies in pooled IgG blocked SEB directly, making it unavailable to the T cells. To determine if pooled IgG interfered with binding of the Staph-toxins to antigen-presenting cells, SEB was allowed to bind at 40C to the lymphoid cells with and without pooled IgG present. The cells were then washed and assayed for proliferation 3 d later. Table IV shows that when SEB and IgG were added together, there was marked inhibition of T cell proliferation (71% inhibition). The table also shows that pretreating the lymphoid cells with IgG before addition ofSEB did not inhibit subsequent T cell proliferation (lines 3 and 4) . Thus, the antibodies were not inhibitory by a direct effect (e.g., anti-idiotype) on the lymphoid cell themselves.
The second experiment in Table IV 
- (8) - (7 (31 ) .
The presence of antibodies to the Staph-toxins in IVIgG shows that normal individuals are naturally exposed to the Staph-toxins. With age normal individuals exhibit an increasing prevalence ofserum antibodies to the Staph-toxins (28, 32, 33, unpublished observation), especially to TSST-l (> 90%) (28, 32, 33) . Clinical infections with Staphylococcus aureus result in a higher prevalence and concentration ofantibodies to the Staph-toxins (34, 35) . Immunocompromised individuals may be exposed to higher concentrations of the Staph-toxins than normal individuals. For example, HIV-infected individuals have a higher incidence of nasal colonization with StaphyProliferation (cpm x 10-3) Figure 3 . Ability of various IgG preparations to inhibit the proliferative response to the Staph-toxins. Varying concentrations of pooled IgG, an F(ab)2 preparation of pooled IgG, an Fc preparation of pooled IgG (top panel) and 1 mg/ml of monoclonal (MC) IgG (bottom panel) were compared for their ability to inhibit T cell proliferation in response to the Staph-toxins (1 ng/ml, except for SEE which was 0.1 ng/ml). 
Discussion
The present study demonstrates that IVIgG inhibits the in vitro stimulation of T cells by Staph-toxin superantigens. High concentrations of antibodies to the Staph-toxins were present in the pooled IgG. Inhibition was mediated by Staph-toxin-specific antibodies; this was shown most definitively by the relative inability of pooled IgG depleted of SEB-specific antibodies to inhibit the response to SEB, while retaining the ability to inhibit the response to the antigenically unrelated TSST-1.
The primary mechanism of inhibition by pooled The presence of antibodies to the Staph-toxin superantigens in pooled IgG raises the possibility ofthe presence ofantibodies to other endogenous superantigens, such as those produced by streptococcal (3, 39) and mycoplasma organisms (40) , as well as other superantigens to which humans may be exposed. Because of an increased presence of certain V , TCR families in autoimmune diseases (9, 12, 13) and because superantigens are the only substances known to activate V j T cell families selectively (3), superantigens have been implicated as etiologic and/or secondary agents in autoimmune disease (9) . For example, excessive cytokine production by superantigenactivated T cells ( 1 ) may exacerbate autoimmune diseases by providing help for autoreactive T and B cells ( 10) . Thus, if superantigens are involved in autoimmune disease, superantigen specific antibodies could play a significant immunoregulatory role.
In conclusion, the mechanism(s) of IVIgG efficacy in a number of diverse disease conditions including Kawasaki disease, idiopathic thrombocytic purpura, systemic juvenile rheumatoid arthritis and HIV infection remains uncertain (18) (19) (20) (21) (22) . However, we believe that the present study showing the ability of antibodies to the Staph-toxins to inhibit T cell activation by these superantigens provides a new insight into further study of the effectiveness of IVIgG in the treatment of disease. 
